<DOC>
	<DOCNO>NCT02211859</DOCNO>
	<brief_summary>Primary : Maximum tolerate dose ( MTD ) Secondary : Determination pharmacokinetic profile BI 2536 . Assessment safety efficacy .</brief_summary>
	<brief_title>Dose Escalation Study BI 2536 BS Patients With Advanced Solid Tumours With Repeated Administration Patients With Clinical Benefit</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : Patients confirm diagnosis advance , non resectable and/or metastatic solid tumour , fail conventional treatment , therapy proven efficacy exists , amenable establish form treatment Evaluable tumour deposit Age 18 year old Life expectancy least six month Written inform consent consistent international conference harmonization ( ICH ) good clinical practice ( GCP ) local legislation Eastern Cooperative Oncology Group ( ECOG ) performance score ≤ 2 Full recovery therapyrelated toxicity previous chemo , hormone , immuno , radiotherapies Serious illness concomitant nononcological disease consider investigator incompatible protocol Pregnancy breastfeed Active infectious disease Known brain metastasis Second malignancy require therapy Absolute neutrophil count le 1500/mm3 Platelet count less 100 000/mm3 Bilirubin great 1.5 mg/dl ( &gt; 26 μmol/L ) Aspartate amino transferase ( AST ) and/or alanine amino transferase ( ALT ) great 2.5 time upper limit normal ( related liver metastasis great five time upper limit normal ) Serum creatinine great 1.5 mg/dl ( &gt; 132 μmol/L ) Women men sexually active unwilling use medically acceptable method contraception Treatment investigational drug participation another clinical trial within past four week start therapy concomitantly trial ( except present trial drug )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>